The present invention relates to the treatment of estrogen-dependent
hyperproliferative uterine disorders including endometriosis, uterine
fibroids, endometrial hyperplasia, uterine cancer, and their related
symptoms by intravaginally administering at least two active agents
selected from an aromatase inhibitor, an antiinflammatory agent, and a
uterine-selective estrogen receptor antagonist. This combination therapy
reduces local estrogen production, blocks local estrogen action, and
suppresses inflammation locally, resulting in starvation of the
estrogen-dependent diseased tissues, relief of related symptoms, and
retardation of disease progression. Intravaginal delivery maximizes local
inhibition of estrogen production without significantly affecting
systemic circulating estrogen levels. This results in enhanced clinical
efficacy and reduced side effects.